Trevi Therapeutics, Inc.

  • Life Sciences
  • Biotechnology
195 Church Street
14th Floor
New Haven, CT 06510
(203) 304-2499
  • About

    Trevi Therapeutics, Inc. is a clinical stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. Prurigo nodularis is a chronic dermatologic condition characterized by pruritic nodules on the skin that are independent of underlying etiology, but instead result as a clinical reaction pattern due to long-term trauma of the pruritic skin. Founded in 2011, Trevi is headquartered in New Haven, CT.